Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jena
Clinical trial register · Germany

Clinical Trials in Jena, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2873
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals21 Merck Sharp & Dohme LLC15 Jena University Hospital11 AstraZeneca11 Takeda6
Site location
Berlin1586 Hamburg889 Essen766 Dresden716 Heidelberg627
All 639 locations
Target enrolment
to

Trials with a site in Jena

205 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Asciminib Frontline Risk Adapted
NCT07804901Chronic Myeloid Leukemia (CML)
DrugDasatinib
Prof. Dr. med. Andreas Hochhaus
Phase 2
200
Jena
2027-01-01
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Essen, Jena
2026-12-31
Not yet open
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-12-14
Not yet open
Dalbavancin Therapy for Infective Endocarditis
NCT07699211Endocarditis Infective, Endocarditis, Bacterial
DrugDalbavancin administration
Stefan Hagel
Phase 3
184
Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena
2026-12
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 3
700
Frankfurt, Göttingen, Jena, Stuttgart
2026-11-16
Not yet open
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
158
Frankfurt am Main, Jena, Rostock
2026-11
Recruiting
Hoffmann-La Roche
Phase 2
45
Greifswald, Jena
2026-10-30
Recruiting
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia
Deepull Diagnostics S.L.
Observational
1,500
Berlin-Zehlendorf, Jena, Leipzig
2026-09-21
Recruiting
Mitral Valve Edge-to-Edge Repair in Patients With Exercise-Induced Severe Mitral Regurgitation
NCT07709208Heart Failure - NYHA II - IV, Mitral Regurgitation Functional
Jena University Hospital
Not applicable
246
Düsseldorf, Jena
2026-09-16
Recruiting
Takeda
Phase 3
324
Freiburg im Breisgau, Heidelberg, Mutlangen, Minden, Koblenz, Chemnitz, Halle, Jena
2026-09-10
Recruiting
Alexandra Miriam Kiess
Not applicable
600
Jena
2026-08-01
Recruiting
Universität Duisburg-Essen
Not applicable
346
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz
2026-07-01
Active, closed
Thomas Ernst, PD Dr. med.
Phase 2
50
Jena
2026-06-22
Recruiting
AstraZeneca
Observational
200
Bochum, Braunschweig, Dortmund, Dresden, Hagen, Hamburg, Heilbronn, Jena
2026-06-10
Recruiting
AstraZeneca
Phase 1/2
152
Essen, Jena, Rostock, Tübingen
2026-06-03
Recruiting
Takeda
Observational
50
Bonn, Cologne, Jena, Leipzig, München
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Jena, Karlshorst
2026-05-23
Recruiting
AstraZeneca
Phase 3
670
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe
2026-05-04
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München
2026-04-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Augsburg, Munich, Jena, Berlin
2026-04-09
Not yet open
University of Leipzig
Observational
100
Berlin, Frankfurt, Hamburg, Hanover, Heidelberg, Herne, Homburg, Jena
2026-04-01
Recruiting
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
NCT06355050Prostate Cancer, Adaptive Radiotherapy, Quality of Life
Jena University Hospital
Observational
150
Jena
2026-04-01
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Jena, Hamburg, Herne, München
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 3
850
Augsburg, Erlangen, Koblenz, Ludwigshafen am Rhein, Magdeburg, Kiel, Jena, Berlin
2026-03-16
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Bad Bevensen, Bad Nauheim, Berlin, Dresden, Hamburg, Jena, Mainz
2026-03-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Jena
2026-02-16
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Düsseldorf, Heidelberg, Jena, Würzburg
2026-02-04
Recruiting
Prilenia
Phase 3
500
Berlin, Bonn, Jena, München, Ulm
2026-02-01
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Tübingen, Jena
2026-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Jena, Berlin
2026-01-19
Recruiting
University Hospital, Grenoble
Observational
1,600
Bayreuth, Göttingen, Jena, Mannheim, Ulm
2026-01-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Jena, Essen
2026-01-13
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Jena, Essen
2025-12-29
Recruiting
Federation Francophone de Cancerologie Digestive
Phase 3
324
Chemnitz, Essen, Frankfurt, Hamburg, Jena, Leipzig, München, Rostock
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg
2025-12-10
Recruiting
Christian Schulze
Phase 3
536
Jena, Bad Nauheim, Berlin, Bonn, Dresden, Göttingen, Halle, Leipzig
2025-12-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Leipzig, Jena, Berlin
2025-12-04
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Bonn, Jena, Mainz, München, Münster
2025-12-02
Recruiting
Amgen
Phase 3
750
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena
2025-11-28
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Heidelberg, Stuttgart, Tübingen, Düsseldorf, Herne, Minden, Chemnitz, Jena
2025-11-25
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
40
Aachen, Bonn, Essen, Frankfurt, Giessen, Göttingen, Hamburg, Jena
2025-11-18
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Leipzig, Halle, Jena
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Düsseldorf, Jena
2025-10-15
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
Bad Oeynhausen, Göttingen, Heidelberg, Jena
2025-10-06
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Not yet open
Imbalances of Regional Pulmonary Ventilation in Patients With Post-acute-COVID-19
NCT05238623COVID-19 Pneumonia, Post-acute COVID-19 Syndrome, Electric Impedance
Jan-Christoph Lewejohann
Observational
50
Jena
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Heidelberg, Nürtingen, Munich, Nuremberg, Regensburg, Hanover, Kiel, Jena
2025-09-30
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
Dresden, Hanover, Jena, Lübeck, Rostock, Ulm
2025-09-17
Recruiting
Takeda
Phase 3
347
Aachen, Jena, Mainz
2025-07-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
360
Heidelberg, Ulm, Jena, Hamburg
2025-07-03
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Jena, Mainz
2025-06-12
Recruiting
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Recruiting
Celgene
Phase 2
200
Würzburg, Kassel, Bochum, Münster, Siegen, Meisenheim, Jena, Bielefeld
2025-06-05
Recruiting
Sanofi
Phase 2
99
Minden, Jena, Kiel, Ulm
2025-06-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Aachen, Trier, Saarbrücken, Leipzig, Jena, Berlin, Hamburg
2025-05-22
Active, closed
Boehringer Ingelheim
Phase 1
91
Braunschweig, Jena, Leipzig, Ulm
2025-05-14
Recruiting
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm
2025-03-17
Active, closed
Celgene
Phase 3
960
Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg
2025-03-13
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
Stuttgart, Munich, Herne, Halle, Jena
2025-03-11
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Essen, Jena, Lübeck, Mannheim
2025-02-28
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Giessen, Hanover, Jena, Tübingen
2025-02-10
Recruiting
LEOPARD Training and Validation Data Collection Study
NCT06675604Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
Assistance Publique - Hôpitaux de Paris
Observational
4,500
Aachen, Berlin, Hanover, Jena, Kiel, Leipzig, Münster, Tübingen
2025-02-04
Recruiting
Takeda
Phase 3
396
Berlin, Frankfurt am Main, Halle, Jena, Kiel, Ludwigshafen, Mannheim
2025-01-02
Recruiting
The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?
NCT06749483Critical Illness, Intensive Care Unit Delirium, Neurocognitive Deficit, Microbiome,immune Function, Critically Ill
Jena University Hospital
Observational
100
Jena
2024-12-27
Recruiting
Cytokinetics
Phase 3
1,800
Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim
2024-12-19
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Recruiting
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
Hanover, Jena
2024-12-09
Active, closed
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Recruiting
BeOne Medicines
Phase 1/2
80
Dresden, Jena, Kiel, Tübingen, Ulm
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Berlin, Chemnitz, Essen, Jena, Würzburg
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Erfurt, Jena
2024-11-21
Recruiting
UCB Biopharma SRL
Phase 3
450
Berlin, Cologne, Dessau, Dresden, Freiburg im Breisgau, Greifswald, Herne, Jena
2024-11-21
Recruiting
argenx
Observational
680
Altenburg, Bochum, Göppingen, Göttingen, Gummersbach, Jena, Würzburg
2024-11-04
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Active, closed
Incyte Corporation
Phase 2
130
Frankfurt am Main, Freiburg I. Breisgau, Hamburg, Jena, Mannheim, Regensburg
2024-10-11
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Würzburg, Jena, Berlin
2024-10-09
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
Homburg, Jena, Munich
2024-10-03
Active, closed
Hoffmann-La Roche
Phase 3
400
Jena
2024-09-17
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
Kyverna Therapeutics
Phase 2/3
66
Berlin, Bochum, Hamburg, Hanover, Jena, Magdeburg, Munich
2024-08-28
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
München, Bremen, Jena, Braunschweig, Berlin, Bad Rothenfelde
2024-08-21
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Düsseldorf, Essen, Freiburg im Breisgau, Giessen, Jena, München, Stuttgart
2024-08-15
Recruiting
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Recruiting
Wuerzburg University Hospital
Observational
200
Würzburg, Jena
2024-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin
2024-07-16
Recruiting
Jena University Hospital
Observational
74
Jena
2024-07-01
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel
2024-06-03
Recruiting
University Hospital Tuebingen
Phase 2
60
Tübingen, Jena
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
510
Berlin, Dresden, Frankfurt am Main, Jena, Lübeck, Sachsen
2024-04-29
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Düsseldorf, Jena
2024-04-22
Recruiting
Stephanie Gräger
Not applicable
80
Jena
2024-04-19
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena
2024-04-18
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Stuttgart, Munich, Dresden, Jena, Berlin, Hamburg
2024-04-10
Recruiting
Cohort Study on Plant-based Diets (COPLANT Study)
NCT06323538Dietary Exposure, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Bone Loss
German Federal Institute for Risk Assessment
Observational
6,000
Karlsruhe, Jena, Berlin, Bonn, Giessen, Heidelberg, Regensburg
2024-04-09
Not yet open
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
NCT05587621ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
Jena University Hospital
Not applicable
300
Jena, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg
2024-04-01
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
330
Aachen, Berlin, Frankfurt am Main, Hanover, Jena, Mannheim, München
2024-03-26
Recruiting
Technische Universität Dresden
Observational
500
Aachen, Chemnitz, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Jena
2024-03-13
Recruiting
Medical University Innsbruck
Not applicable
1,350
Essen, Freiburg im Breisgau, Giessen, Jena
2024-03-12
Recruiting
Edward Geissler
Phase 4
300
Aachen, Berlin, Dresden, Hamburg, Hanover, Jena, Mainz, Münster
2024-03-09
Recruiting
Heidelberg University
Not applicable
304
Berlin, Düsseldorf, Heidelberg, Jena, Ulm
2024-02-28
Recruiting
Aleksander Krag
Phase 3
240
Berlin, Jena, Münster
2024-02-26
Active, closed
AbbVie
Observational
1,200
Dachau, Lüneburg, Oldenburg, Minden, Buedelsdorf, Lübeck, Jena, Berlin
2024-02-19
Recruiting
University of Leipzig
Phase 3
188
Borna, Cottbus, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Jena, Leipzig
2024-01-24
Recruiting
Colorado Prevention Center
Phase 3
5,200
Lübeck, Berlin, Jena, Dresden, Giessen, Regensburg
2024-01-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Munich, Schwerin, Bonn, Münster, Lübeck, Jena, Berlin, Hamburg
2023-12-31
Active, closed
Sanofi
Phase 3
943
Bielefeld, Bochum, Dresden, Düsseldorf, Erbach im Odenwald, Essen, Heidelberg, Jena
2023-12-27
Active, closed
medac GmbH
Phase 2
49
Aachen, Essen, Frankfurt, Freiburg im Breisgau, Giessen, Hanover, Jena, Leipzig
2023-11-13
Recruiting
Takeda
Phase 3
80
Würzburg, Münster, Jena, Hamburg, Hanover
2023-11-13
Active, closed
Summit Therapeutics
Phase 3
1,600
Esslingen am Neckar, Frankfurt, Gauting, Giesen, Heidelberg, Jena, Kempten, Lübeck
2023-10-26
Active, closed
Bristol-Myers Squibb
Phase 3
402
Erding, Münster, Koblenz, Leipzig, Jena, Berlin, Düsseldorf, Lübeck
2023-10-24
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover
2023-10-02
Active, closed
Boehringer Ingelheim
Phase 2
268
Berlin, Essen, Frankfurt, Großhansdorf, Hanover, Immenhausen, Jena, Konstanz
2023-09-08
Recruiting
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
NCT05926505Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID
DrugAnakinra
Hellenic Institute for the Study of Sepsis
Phase 2/3
182
Jena
2023-09-06
Recruiting
Jena University Hospital
Observational
100
Freiburg im Breisgau, Ulm, Münster, Halle, Jena
2023-09-05
Active, closed
Cytokinetics
Phase 3
500
Berlin, Göttingen, Heidelberg, Jena
2023-08-31
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Dresden, Jena, Giessen
2023-08-16
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen
2023-07-06
Recruiting
Heinrich-Heine University, Duesseldorf
Phase 1/2
38
Aachen, Düsseldorf, Cologne, Frankfurt, Jena, München
2023-06-26
Recruiting
The DefiPace Study
NCT04804748Post-operative Atrial Fibrillation POAF
Institut für Pharmakologie und Präventive Medizin
Observational
450
Erlangen, Nuremberg, Würzburg, Oldenburg, Dresden, Freiburg im Breisgau, Hanover, Jena
2023-03-28
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,650
Bochum, Bonn, Cologne, Essen, Frankfurt, Jena, Leipzig, Regensburg
2023-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Frankfurt am Main, Dresden, Jena, Essen, Giessen
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Cologne, Dresden, Jena
2023-02-02
Active, closed
Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis
NCT03843385Ulcerative Colitis, Inflammatory Bowel Diseases
Andreas Stallmach
Phase 3
84
Jena, Bamberg, Berlin, Dresden, Erlangen, Frankfurt, Freiburg im Breisgau, Fulda
2023-01-31
Active, closed
Bristol-Myers Squibb
Phase 3
606
Ulm, Munich, Hanover, Dortmund, Kiel, Jena, Berlin, Cologne
2023-01-10
Active, closed
Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
NCT05524012Locally Advanced Rectal Carcinoma, Neoadjuvant Treatment, Radiotherapy, Adaptive Treatment
Jena University Hospital
Observational
40
Jena
2022-11-30
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
297
Berlin, Cologne, Essen, Frankfurt, Giessen, Halle, Hanover, Jena
2022-11-23
Active, closed
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324Amyotrophic Lateral Sclerosis
Corcept Therapeutics
Phase 2
279
Berlin, Bonn, Dresden, Hanover, Jena, München, Rostock, Ulm
2022-11-15
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 3
822
Berlin, Erlangen, Essen, Frankfurt, Giessen, Hanover, Jena, Mainz
2022-11-08
Active, closed
GlaxoSmithKline
Phase 2
351
Berlin, Essen, Großhansdorf, Heidelberg, Jena
2022-10-14
Active, closed
AudioCure Pharma GmbH
Phase 2
210
Bensheim, Berlin, Dresden, Greifswald, Halle, Hamburg, Jena, Mainz
2022-10-13
Active, closed
University of Leipzig
Observational
60
Berlin, Chemnitz, Dresden, Düsseldorf, Jena, Leipzig, Mainz, Mannheim
2022-10-11
Recruiting
European Myeloma Network B.V.
Phase 3
1,594
Hamburg, Heidelberg, Jena, Lübeck, München, Nuremberg, Tübingen, Würzburg
2022-09-08
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Frankfurt am Main, Jena, Berlin, Kiel
2022-08-30
Recruiting
CytOSorb TreatMent Of Critically Ill PatientS Registry
NCT05146336Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
CytoSorbents, Inc
Observational
3,000
Aachen, Bad Oeynhausen, Bochum, Essen, Göttingen, Herford, Jena, Kassel
2022-06-22
Recruiting
Priothera SAS
Phase 3
366
Freiburg im Breisgau, Halle, Jena, Leipzig, Munich
2022-06-16
Active, closed
AMP SCZ® Observational Study: PREDICT-DPACC
NCT05905003Clinical High Risk, Psychosis, Remission, Conversion
Brigham and Women's Hospital
Observational
2,617
Cologne, Jena, Munich
2022-06-02
Recruiting
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
NCT05304377Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Cml
DrugELVN-001
Enliven Therapeutics
Phase 1
250
Aachen, Berlin, Frankfurt, Homburg, Jena, Mannheim, Rostock
2022-05-22
Recruiting
Electra Therapeutics Inc.
Phase 2/3
156
Jena, Villingen-Schwenningen
2022-05-19
By invitation
Longitudinal Assessment of Pain-Related Patient-Reported Outcomes After Surgery
NCT05315596Pain, Postoperative, Adult, Pain Measurement, Functional Status
Jena University Hospital
Observational
1,000
Jena
2022-02-01
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
München, Essen, Münster, Leipzig, Berlin, Jena
2021-12-14
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Essen, Hamburg, Heidelberg, Herne, Jena, München, Nürtingen, Trier
2021-12-14
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Giessen, Hanover, Jena, München, Rostock
2021-12-10
Recruiting
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
NCT04996433Persistent Depressive Disorder, Treatment-resistant Depression
University of Greifswald
Not applicable
396
Berlin, Bonn, Hanover, Jena, Lübeck, Marburg, München, Tübingen
2021-12-01
Active, closed
Amgen
Phase 3
303
Augsburg, Berlin, Dresden, Düsseldorf, Heidelberg, Jena, Kiel, München
2021-11-02
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Mannheim, Frankfurt am Main, Jena, Aachen, Berlin, Lübeck
2021-10-06
Active, closed
Regeneron Pharmaceuticals
Observational
717
Mannheim, Berlin, Hennigsdorf, Wiesbaden, Düsseldorf, Münster, Dresden, Jena
2021-08-12
Active, closed
Biotronik AG
Observational
160
Bayreuth, Essen, Flensburg, Jena, Münster, Tübingen
2021-08-10
Recruiting
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
NCT04284839Bleeding Post Cardiac Surgery, Indication for Anticoagulation
DrugsDOAC·Dabigatran·Edoxaban·Warfarin
Population Health Research Institute
Phase 3
3,500
Leipzig, Jena, Bonn, Essen, Hamburg
2021-07-18
Recruiting
University of Jena
Observational
200
Jena
2021-07-01
Recruiting
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
NCT05337631HNSCC, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer
University Hospital Freiburg
Observational
1,500
Berlin, Erlangen, Frankfurt, Giessen, Halle, Jena, Kiel, Leipzig
2021-06-01
Active, closed
Pfizer
Phase 3
599
Göttingen, Wesel, Jena, Berlin, Duisburg, Frankfurt, Heidelberg, Leipzig
2021-05-12
By invitation
Cytokinetics
Phase 2/3
900
Berlin, Essen, Goettigen, Heidelberg, Jena, Würzburg
2021-05-06
Active, closed
SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)
NCT04470934Coronary Artery Disease, Myocardial Ischaemia
B. Braun Melsungen AG
Observational
1,302
Jena
2021-04-30
Active, closed
Takeda
Phase 3
77
Hamburg, Jena
2021-04-14
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
Mutlangen, Düsseldorf, Halle, Kiel, Jena
2021-03-11
Recruiting
Syndax Pharmaceuticals
Phase 2
296
Dresden, Jena, Leipzig, Mainz, Münster, Regensburg
2021-03-04
Active, closed
Celgene
Phase 3
313
Aachen, Baden-Warttemberg, Düsseldorf, Halle, Hamburg, Jena, Leipzig, Mannheim
2021-02-25
Recruiting
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
NCT04761120Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease
Abbott Medical Devices
Observational
550
Passau, Würzburg, Bremen, Dresden, Jena
2021-02-01
Active, closed
Amgen
Phase 1/2
181
Augsburg, Berlin, Cologne, Jena, Leipzig, Tübingen, Ulm
2021-01-04
Active, closed
Edward Geissler
Phase 4
268
Aachen, Berlin, Essen, Frankfurt, Hamburg, Hanover, Heidelberg, Jena
2020-12-23
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
55
Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München
2020-12-15
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Cloppenburg, Hanover, Hoyerswerda, Jena, Villingen-Schwenningen, Würzburg
2020-12-11
Active, closed
AstraZeneca
Phase 3
957
Berlin, Dresden, Frankfurt, Hamburg, Heidelberg, Heilbronn, Jena, Mainz Am Rhein
2020-11-17
Recruiting
Occlutech International AB
Observational
150
Bottrop, Coburg, Cologne, Erfurt, Hamburg, Heide, Jena, Osnabrück
2020-10-28
Recruiting
Institut Cancerologie de l'Ouest
Observational
300
Freiburg im Breisgau, Giessen, Jena
2020-07-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Göttingen, Minden, Münster, Neuss, Großhansdorf, Bad Berka, Jena, Berlin
2020-07-06
Recruiting
Jena University Hospital
Phase 2
50
München, Würzburg, Jena, Hanover, Berlin, Bochum, Düsseldorf, Erlangen
2020-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
755
Tübingen, Düsseldorf, Essen, Dresden, Magdeburg, Jena, Berlin, Hamburg
2020-02-27
Recruiting
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665Atrial Fibrillation, Stroke, Bleeding
Icahn School of Medicine at Mount Sinai
Phase 3
3,200
Berlin, Göttingen, Jena, Bad Nauheim, Bad Neustadt an der Saale, Bad Oeynhausen, Bonn, Braunschweig
2019-12-13
Active, closed
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Abiomed Inc.
Not applicable
527
Würzburg, Düsseldorf, Essen, Trier, Dresden, Jena, Marburg, Zwickau
2019-12-12
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
50
Dresden, Essen, Halle, Hanover, Jena, Munich
2019-11-01
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Jena, Essen, Heidelberg, Ulm
2019-10-30
Active, closed
Pazopanib Vs. Pazopanib Plus Gemcitabine
NCT02203760Leiomyosarcoma or Carcinosarcoma
DrugsPazopanib·Gemcitabine
North Eastern German Society of Gynaecological Oncology
Phase 2
58
Bonn, Berlin, Greifswald, Bad Saarow, Dresden, Essen, Jena, Tübingen
2019-10-16
Recruiting
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
DrugWarfarin
Population Health Research Institute
Phase 3
2,625
Giessen, Jena
2019-09-05
Active, closed
Nyxoah S.A.
Not applicable
110
Hamburg, Jena, Mannheim, München, Wuppertal
2019-09-01
Active, closed
Exelixis
Phase 3
855
Heidelberg, Tübingen, Frankfurt am Main, Münster, Mainz, Jena, Dresden
2019-06-25
Active, closed
Eisai Inc.
Phase 2
100
Freiburg im Breisgau, Jena, Munich, Radeberg
2019-05-31
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609Parkinson Disease, Essential Tremor, Dystonia
Boston Scientific Corporation
Observational
5,000
Cologne, Düsseldorf, Jena, Lübeck, Würzburg
2019-03-12
Recruiting
University of Aarhus
Not applicable
750
Jena
2019-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Munich, Weiden in Der Oberpfalz, Würzburg, Trier, Jena
2018-12-24
Active, closed
AstraZeneca
Phase 3
1,063
Bergisch Gladbach, Bonn, Cologne, Erlangen, Göttingen, Herne, Jena, Magdeburg
2018-11-16
Active, closed
AbbVie
Phase 3
265
Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg
2018-10-22
Active, closed
Gilead Sciences
Phase 2
502
Duisburg, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Herne, Jena, Koblenz
2018-08-13
Recruiting
Jena University Hospital
Not applicable
40
Jena, Tübingen
2018-04-10
Recruiting
Randomization of Single vs Multiple Arterial Grafts
NCT03217006Coronary Artery Disease, Heart Diseases
Weill Medical College of Cornell University
Not applicable
4,300
Duisburg, Düsseldorf, Erlangen, Giessen, Göttingen, Jena, Leipzig, Oeynhausen
2018-01-07
Active, closed
Jena University Hospital
Observational
750
Jena
2018-01-01
Active, closed
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
112
Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm
2017-11-27
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
4,975
Berlin, Dresden, Greifswald, Jena, Leer
2017-05-03
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Dresden, Essen, Freiburg im Breisgau, Hamburg, Hanover, Jena, Mannheim, Nuremberg
2017-03-24
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 2
87
Aachen, Berlin, Bonn, Düsseldorf, Halle, Hamburg, Jena, Mainz
2016-12-21
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Berlin, Braunschweig, Düsseldorf, Frankfurt, Hamburg, Jena, Kiel, Lübeck
2016-12
Recruiting
UMC Utrecht
Phase 3
20,000
Berlin, Cologne, Cottbus, Dortmund, Essen, Frankfurt, Hamburg, Jena
2016-04-11
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Braunschweig, Chemnitz, Dessau, Frankfurt, Gronau, Jena, Münster, Nürtingen
2015-11-19
Active, closed
AstraZeneca
Phase 3
1,126
Düsseldorf, Erlangen, Hanover, Heidelberg, Jena, München, Münster
2015-11-02
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Cologne, Jena, Heidelberg
2015-03-06
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Dresden, Jena, Aachen, Hamburg, Magdeburg, Mainz, Ulm
2015-03-05
Active, closed
Eli Lilly and Company
Phase 2
110
Jena, Mannheim, Minden
2012-05-22
Recruiting
University of Jena
Observational
200,000
Jena
2009-01
Rows per page Showing 1–205 of 205
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/jena

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 205 of those studies with a site in Jena.

How many clinical trials are recruiting in Jena?

117 of the 205 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 9 have not yet opened recruitment, 77 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jena), 205 studies
PhaseStudiesRecruitingShare
Phase 3844441%
Phase 2381618.5%
Observational372618%
Not applicable14106.8%
Phase 1/212105.9%
Phase 11044.9%
Phase 2/3652.9%
Phase 4422%

Most active sponsors

Lead sponsors with the most studies (Jena)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals216
Merck Sharp & Dohme LLC159
AstraZeneca118
Jena University Hospital117
Bristol-Myers Squibb63
Takeda65
Janssen Research & Development, LLC55
Amgen41
European Organisation for Research and Treatment of Cancer - EORTC42
Hoffmann-La Roche42
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.